- ISIN
- US74366E1029
- CUSIP
- 74366E102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 11, 2016
Highlights
- Market Cap
- $8.11B
- Enterprise Value
- $7.93B
- EPS (TTM)
- -$1.76
- Total Revenue (TTM)
- $17.70M
- Gross Profit (TTM)
- $17.32M
- EBITDA (TTM)
- -$127.71M
- Year Range
- $49.38 - $116.57
- Target Price
- $116.75
- ROA (TTM)
- -16.45%
- ROE (TTM)
- -17.50%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PTGX Performance Chart
Protagonist Therapeutics Inc (PTGX) is up 31.7% since the beginning of the year. At $115 per share, PTGX is trading just below its 52-week high of $117. Investors who bought $1,000 worth of PTGX shares 5 years ago would now be looking at an investment worth $2,659.
Loading charts...
Returns By Period
Protagonist Therapeutics Inc (PTGX) has returned 31.70% so far this year and 115.65% over the past 12 months.
Protagonist Therapeutics Inc
- 1D
- 1.92%
- 1M
- 15.97%
- YTD
- 31.70%
- 6M
- 31.60%
- 1Y
- 115.65%
- 3Y*
- 60.91%
- 5Y*
- 21.60%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PTGX Monthly Returns History
Based on dividend-adjusted daily data since Aug 11, 2016, PTGX's average daily return is +0.25%, while the average monthly return is +4.75%. At this rate, an investment would double in approximately 1.2 years.
Historically, 55% of months were positive and 45% were negative. The best month was May 2020 with a return of +144.9%, while the worst month was Sep 2021 at -63.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, PTGX closed higher 50% of trading days. The best single day was Oct 11, 2021 with a return of +93.9%, while the worst single day was Sep 17, 2021 at -62.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.34% | 12.57% | 14.47% | -6.10% | 0.60% | 15.54% | 31.70% | ||||||
| 2025 | -2.07% | -0.56% | 28.65% | -5.25% | 3.60% | 16.43% | -2.55% | 9.64% | 12.50% | 18.35% | 14.47% | -2.96% | 126.27% |
| 2024 | 9.07% | 21.47% | -4.77% | -13.20% | 12.11% | 23.09% | 8.05% | 14.56% | 4.92% | 1.87% | -4.45% | -11.87% | 68.34% |
| 2023 | 21.81% | 22.05% | 41.80% | -1.74% | 15.35% | 5.95% | -29.76% | 2.16% | -15.84% | -12.83% | 25.24% | 25.92% | 110.17% |
| 2022 | -14.36% | -17.10% | -2.47% | -61.61% | -3.63% | -9.70% | 25.79% | -12.36% | -3.33% | -3.91% | -2.35% | 37.93% | -68.10% |
| 2021 | 2.73% | 13.81% | 9.89% | 11.74% | 21.32% | 27.83% | 10.14% | -1.88% | -63.46% | 75.85% | 7.89% | 1.73% | 69.64% |
Benchmark Metrics
Protagonist Therapeutics Inc has an annualized alpha of 62.77%, beta of 1.01, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since August 11, 2016.
- This stock captured 220.28% of S&P 500 Index gains and 153.47% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 62.77%
- Beta
- 1.01
- R²
- 0.04
- Upside Capture
- 220.28%
- Downside Capture
- 153.47%
Return for Risk
Risk / Return Rank
PTGX ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Protagonist Therapeutics Inc (PTGX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PTGX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.25 | ||
| Sortino ratioReturn per unit of downside risk | +0.49 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.37 | +0.04 |
| Calmar ratioReturn relative to maximum drawdown | 7.10 | 2.78 | +4.32 |
| Martin ratioReturn relative to average drawdown | 16.26 | 12.44 | +3.82 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Protagonist Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Protagonist Therapeutics Inc was 85.79%, occurring on Jun 13, 2022. Recovery took 686 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -85.79%Jun 2022 | 9mo 14d | 2y 9mo | 3y 6moSep 2021 - Mar 2025 |
2019 bear market2019 | -82.13%Dec 2019 | 2y 12mo | 1y 2mo | 4y 2moDec 2016 - Feb 2021 |
2025 selloff2025 | -31.58%Apr 2025 | 29d | 4mo 19d | 5mo 18dMar 2025 - Aug 2025 |
2016 bear market2016 | -20.33%Nov 2016 | 14d | 9d | 23dOct 2016 - Nov 2016 |
2021 correction2021 | -19.04%Mar 2021 | 7d | 1mo 20d | 1mo 27dMar 2021 - May 2021 |
Drawdown Indicators
| PTGX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.79% | -56.78% | -29.01% |
Max Drawdown (1Y)Largest decline over 1 year | -16.38% | -9.10% | -7.28% |
Max Drawdown (3Y)Largest decline over 3 years | -51.13% | -18.90% | -32.23% |
Max Drawdown (5Y)Largest decline over 5 years | -85.79% | -25.43% | -60.36% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | 0.00% | -1.80% | +1.80% |
Average DrawdownAverage peak-to-trough decline | -40.59% | -10.71% | -29.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.14% | 2.03% | +5.11% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Protagonist Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Protagonist Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PTGX relative to other companies in the Biotechnology industry. Currently, PTGX has a P/S ratio of 424.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PTGX in comparison with other companies in the Biotechnology industry. Currently, PTGX has a P/B value of 12.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PTGX
Add Protagonist Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PTGX